These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

354 related items for PubMed ID: 8361761

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Transformation by the vRel oncoprotein requires sequences carboxy-terminal to the Rel homology domain.
    Sarkar S, Gilmore TD.
    Oncogene; 1993 Aug; 8(8):2245-52. PubMed ID: 8336947
    [Abstract] [Full Text] [Related]

  • 7. v-rel- and c-rel-protein complexes bind to the NF-kappa B site in vitro.
    Kochel T, Rice NR.
    Oncogene; 1992 Mar; 7(3):567-72. PubMed ID: 1549370
    [Abstract] [Full Text] [Related]

  • 8. Mutant envelope residues confer a transactivation function onto N-terminal sequences of the v-Rel oncoprotein.
    Epinat JC, Kazandjian D, Harkness DD, Petros S, Dave J, White DW, Gilmore TD.
    Oncogene; 2000 Feb 03; 19(5):599-607. PubMed ID: 10698504
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Mutations of tumor necrosis factor alpha-responsive serine residues within the C-terminal transactivation domain of human transcription factor REL enhance its in vitro transforming ability.
    Starczynowski DT, Reynolds JG, Gilmore TD.
    Oncogene; 2005 Nov 10; 24(49):7355-68. PubMed ID: 16027730
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Selective activation of the proto-oncogene c-jun promoter by the transforming protein v-Rel.
    Fujii M, Minamino T, Nomura M, Miyamoto KI, Tanaka J, Seiki M.
    Oncogene; 1996 May 16; 12(10):2193-202. PubMed ID: 8668346
    [Abstract] [Full Text] [Related]

  • 15. The v-rel oncogene promotes malignant T-cell leukemia/lymphoma in transgenic mice.
    Carrasco D, Rizzo CA, Dorfman K, Bravo R.
    EMBO J; 1996 Jul 15; 15(14):3640-50. PubMed ID: 8670867
    [Abstract] [Full Text] [Related]

  • 16. rel/NF-kappa B nuclear complexes that bind kB sites in the murine c-rel promoter are required for constitutive c-rel transcription in B-cells.
    Grumont RJ, Richardson IB, Gaff C, Gerondakis S.
    Cell Growth Differ; 1993 Sep 15; 4(9):731-43. PubMed ID: 8241021
    [Abstract] [Full Text] [Related]

  • 17. Two novel functions associated with the Rel oncoproteins: DNA replication and cell-specific transcriptional activation.
    Ishikawa H, Asano M, Kanda T, Kumar S, Gélinas C, Ito Y.
    Oncogene; 1993 Nov 15; 8(11):2889-96. PubMed ID: 8414493
    [Abstract] [Full Text] [Related]

  • 18. Involvement of Ets, rel and Sp1-like proteins in lipopolysaccharide-mediated activation of the HIV-1 LTR in macrophages.
    Sweet MJ, Stacey KJ, Ross IL, Ostrowski MC, Hume DA.
    J Inflamm; 1998 Nov 15; 48(2):67-83. PubMed ID: 9656143
    [Abstract] [Full Text] [Related]

  • 19. Transactivation of the GATA-1 promoter by a myb-ets-containing mouse retrovirus is mediated by CACCC elements.
    Sun-Hoffman L, Aurigemma RE, Sun B, Ruscetti SK.
    Oncogene; 1996 Sep 05; 13(5):1037-42. PubMed ID: 8806693
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 18.